Your browser doesn't support javascript.
loading
Chronic treatment of non-small-cell lung cancer cells with gefitinib leads to an epigenetic loss of epithelial properties associated with reductions in microRNA-155 and -200c.
Narita, Michiko; Shimura, Eri; Nagasawa, Atsumi; Aiuchi, Toshiki; Suda, Yukari; Hamada, Yusuke; Ikegami, Daigo; Iwasawa, Chizuru; Arakawa, Kazuhiko; Igarashi, Katsuhide; Kuzumaki, Naoko; Yoshioka, Yusuke; Ochiya, Takahiro; Takeshima, Hideyuki; Ushijima, Toshikazu; Narita, Minoru.
Afiliação
  • Narita M; Department of Pharmacology, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Ebara, Shinagawa-ku, Tokyo, Japan.
  • Shimura E; Department of Pharmacology, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Ebara, Shinagawa-ku, Tokyo, Japan.
  • Nagasawa A; Department of Pharmacology, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Ebara, Shinagawa-ku, Tokyo, Japan.
  • Aiuchi T; Department of Pharmacology, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Ebara, Shinagawa-ku, Tokyo, Japan.
  • Suda Y; Department of Pharmacology, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Ebara, Shinagawa-ku, Tokyo, Japan.
  • Hamada Y; Department of Pharmacology, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Ebara, Shinagawa-ku, Tokyo, Japan.
  • Ikegami D; Department of Pharmacology, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Ebara, Shinagawa-ku, Tokyo, Japan.
  • Iwasawa C; Department of Pharmacology, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Ebara, Shinagawa-ku, Tokyo, Japan.
  • Arakawa K; Department of Pharmacology, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Ebara, Shinagawa-ku, Tokyo, Japan.
  • Igarashi K; Life Science Tokyo Advanced Research Center (L-StaR), Hoshi University School of Pharmacy and Pharmaceutical Sciences, Ebara, Shinagawa-ku, Tokyo, Japan.
  • Kuzumaki N; Department of Pharmacology, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Ebara, Shinagawa-ku, Tokyo, Japan.
  • Yoshioka Y; Division of Molecular and Cellular Medicine, National Cancer Center Research Institute, Tsukiji, Chuo-ku, Tokyo, Japan.
  • Ochiya T; Department of Pharmacology, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Ebara, Shinagawa-ku, Tokyo, Japan.
  • Takeshima H; Division of Molecular and Cellular Medicine, National Cancer Center Research Institute, Tsukiji, Chuo-ku, Tokyo, Japan.
  • Ushijima T; Division of Epigenomics, National Cancer Center Research Institute, Tsukiji, Chuo-ku, Tokyo, Japan.
  • Narita M; Life Science Tokyo Advanced Research Center (L-StaR), Hoshi University School of Pharmacy and Pharmaceutical Sciences, Ebara, Shinagawa-ku, Tokyo, Japan.
PLoS One ; 12(2): e0172115, 2017.
Article em En | MEDLINE | ID: mdl-28225782
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Quinazolinas / Carcinoma Pulmonar de Células não Pequenas / MicroRNAs / Epigênese Genética / Neoplasias Pulmonares / Antineoplásicos Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Revista: PLoS One Assunto da revista: CIENCIA / MEDICINA Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Japão
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Quinazolinas / Carcinoma Pulmonar de Células não Pequenas / MicroRNAs / Epigênese Genética / Neoplasias Pulmonares / Antineoplásicos Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Revista: PLoS One Assunto da revista: CIENCIA / MEDICINA Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Japão